Qudexy Xr

Migraine, Caloric Restriction, High cholesterol + 16 more
Treatment
20 Active Studies for Qudexy Xr

What is Qudexy Xr

TopiramateThe Generic name of this drug
Treatment SummaryTopiramate is a medication used to control epilepsy and prevent migraine headaches. It was first approved by the FDA in 1996 and later approved for migraine prevention in adults in 2004. It is also used in combination with another drug, phentermine, to help adults lose weight. It has an unusual chemical structure composed of sulfamate and oxygen, which was discovered by chance during the development of an antidiabetic medication.
Topamaxis the brand name
image of different drug pills on a surface
Qudexy Xr Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Topamax
Topiramate
1997
526

Effectiveness

How Qudexy Xr Affects PatientsTopiramate helps to prevent seizures and migraine symptoms by decreasing the activity of neurons in the brain. However, it can also cause metabolic acidosis, changes in mood, suicidal thoughts or attempts, and kidney stones. Taking topiramate with another drug called valproic acid can also lead to hypothermia.
How Qudexy Xr works in the bodySeizures are caused by an electrical disruption in the brain, which causes a temporary disruption of normal brain activity. Topiramate is used to treat these seizures and migraines, although the exact way it works is not fully understood. It likely works by blocking sodium channels in the brain and increasing activity of inhibitory GABA-A receptors while reducing activity of stimulating glutamate receptors. This decreases the electrical signals in the brain, preventing seizures and migraines. Topiramate also blocks some carbonic anhydrase isozymes, but it is unclear what impact this has.

When to interrupt dosage

The recommended dosage of Qudexy Xr is contingent upon the diagnosed condition, including Seizures, Weight Reduction and Tonic - clonic seizures. The quantity of dosage fluctuates as per the procedure of delivery (e.g. Tablet, coated or Tablet) specified in the table underneath.
Condition
Dosage
Administration
Obesity
, 25.0 mg, 100.0 mg, 200.0 mg, 50.0 mg, 150.0 mg, 15.0 mg, 23.0 mg, 46.0 mg, 69.0 mg, 92.0 mg, 25.0 meq, 25.0 mg/mL
, Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, extended release, Capsule, extended release - Oral, Capsule, coated pellets, Capsule, coated pellets - Oral, Capsule, Capsule - Oral, Solution - Oral, Solution
Exercise
, 25.0 mg, 100.0 mg, 200.0 mg, 50.0 mg, 150.0 mg, 15.0 mg, 23.0 mg, 46.0 mg, 69.0 mg, 92.0 mg, 25.0 meq, 25.0 mg/mL
, Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, extended release, Capsule, extended release - Oral, Capsule, coated pellets, Capsule, coated pellets - Oral, Capsule, Capsule - Oral, Solution - Oral, Solution
Lennox Gastaut Syndrome
, 25.0 mg, 100.0 mg, 200.0 mg, 50.0 mg, 150.0 mg, 15.0 mg, 23.0 mg, 46.0 mg, 69.0 mg, 92.0 mg, 25.0 meq, 25.0 mg/mL
, Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, extended release, Capsule, extended release - Oral, Capsule, coated pellets, Capsule, coated pellets - Oral, Capsule, Capsule - Oral, Solution - Oral, Solution
Alcoholism
, 25.0 mg, 100.0 mg, 200.0 mg, 50.0 mg, 150.0 mg, 15.0 mg, 23.0 mg, 46.0 mg, 69.0 mg, 92.0 mg, 25.0 meq, 25.0 mg/mL
, Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, extended release, Capsule, extended release - Oral, Capsule, coated pellets, Capsule, coated pellets - Oral, Capsule, Capsule - Oral, Solution - Oral, Solution
Migraine
, 25.0 mg, 100.0 mg, 200.0 mg, 50.0 mg, 150.0 mg, 15.0 mg, 23.0 mg, 46.0 mg, 69.0 mg, 92.0 mg, 25.0 meq, 25.0 mg/mL
, Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, extended release, Capsule, extended release - Oral, Capsule, coated pellets, Capsule, coated pellets - Oral, Capsule, Capsule - Oral, Solution - Oral, Solution
Caloric Restriction
, 25.0 mg, 100.0 mg, 200.0 mg, 50.0 mg, 150.0 mg, 15.0 mg, 23.0 mg, 46.0 mg, 69.0 mg, 92.0 mg, 25.0 meq, 25.0 mg/mL
, Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, extended release, Capsule, extended release - Oral, Capsule, coated pellets, Capsule, coated pellets - Oral, Capsule, Capsule - Oral, Solution - Oral, Solution
High cholesterol
, 25.0 mg, 100.0 mg, 200.0 mg, 50.0 mg, 150.0 mg, 15.0 mg, 23.0 mg, 46.0 mg, 69.0 mg, 92.0 mg, 25.0 meq, 25.0 mg/mL
, Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, extended release, Capsule, extended release - Oral, Capsule, coated pellets, Capsule, coated pellets - Oral, Capsule, Capsule - Oral, Solution - Oral, Solution
Obesity
, 25.0 mg, 100.0 mg, 200.0 mg, 50.0 mg, 150.0 mg, 15.0 mg, 23.0 mg, 46.0 mg, 69.0 mg, 92.0 mg, 25.0 meq, 25.0 mg/mL
, Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, extended release, Capsule, extended release - Oral, Capsule, coated pellets, Capsule, coated pellets - Oral, Capsule, Capsule - Oral, Solution - Oral, Solution
at least one weight-related comorbid condition
, 25.0 mg, 100.0 mg, 200.0 mg, 50.0 mg, 150.0 mg, 15.0 mg, 23.0 mg, 46.0 mg, 69.0 mg, 92.0 mg, 25.0 meq, 25.0 mg/mL
, Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, extended release, Capsule, extended release - Oral, Capsule, coated pellets, Capsule, coated pellets - Oral, Capsule, Capsule - Oral, Solution - Oral, Solution
Migraine Disorders
, 25.0 mg, 100.0 mg, 200.0 mg, 50.0 mg, 150.0 mg, 15.0 mg, 23.0 mg, 46.0 mg, 69.0 mg, 92.0 mg, 25.0 meq, 25.0 mg/mL
, Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, extended release, Capsule, extended release - Oral, Capsule, coated pellets, Capsule, coated pellets - Oral, Capsule, Capsule - Oral, Solution - Oral, Solution
Obesity
, 25.0 mg, 100.0 mg, 200.0 mg, 50.0 mg, 150.0 mg, 15.0 mg, 23.0 mg, 46.0 mg, 69.0 mg, 92.0 mg, 25.0 meq, 25.0 mg/mL
, Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, extended release, Capsule, extended release - Oral, Capsule, coated pellets, Capsule, coated pellets - Oral, Capsule, Capsule - Oral, Solution - Oral, Solution
Seizures
, 25.0 mg, 100.0 mg, 200.0 mg, 50.0 mg, 150.0 mg, 15.0 mg, 23.0 mg, 46.0 mg, 69.0 mg, 92.0 mg, 25.0 meq, 25.0 mg/mL
, Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, extended release, Capsule, extended release - Oral, Capsule, coated pellets, Capsule, coated pellets - Oral, Capsule, Capsule - Oral, Solution - Oral, Solution
Type 2 Diabetes
, 25.0 mg, 100.0 mg, 200.0 mg, 50.0 mg, 150.0 mg, 15.0 mg, 23.0 mg, 46.0 mg, 69.0 mg, 92.0 mg, 25.0 meq, 25.0 mg/mL
, Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, extended release, Capsule, extended release - Oral, Capsule, coated pellets, Capsule, coated pellets - Oral, Capsule, Capsule - Oral, Solution - Oral, Solution
Hypertensive disease
, 25.0 mg, 100.0 mg, 200.0 mg, 50.0 mg, 150.0 mg, 15.0 mg, 23.0 mg, 46.0 mg, 69.0 mg, 92.0 mg, 25.0 meq, 25.0 mg/mL
, Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, extended release, Capsule, extended release - Oral, Capsule, coated pellets, Capsule, coated pellets - Oral, Capsule, Capsule - Oral, Solution - Oral, Solution
Epilepsy
, 25.0 mg, 100.0 mg, 200.0 mg, 50.0 mg, 150.0 mg, 15.0 mg, 23.0 mg, 46.0 mg, 69.0 mg, 92.0 mg, 25.0 meq, 25.0 mg/mL
, Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, extended release, Capsule, extended release - Oral, Capsule, coated pellets, Capsule, coated pellets - Oral, Capsule, Capsule - Oral, Solution - Oral, Solution
Weight Loss
, 25.0 mg, 100.0 mg, 200.0 mg, 50.0 mg, 150.0 mg, 15.0 mg, 23.0 mg, 46.0 mg, 69.0 mg, 92.0 mg, 25.0 meq, 25.0 mg/mL
, Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, extended release, Capsule, extended release - Oral, Capsule, coated pellets, Capsule, coated pellets - Oral, Capsule, Capsule - Oral, Solution - Oral, Solution
increase in physical activity
, 25.0 mg, 100.0 mg, 200.0 mg, 50.0 mg, 150.0 mg, 15.0 mg, 23.0 mg, 46.0 mg, 69.0 mg, 92.0 mg, 25.0 meq, 25.0 mg/mL
, Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, extended release, Capsule, extended release - Oral, Capsule, coated pellets, Capsule, coated pellets - Oral, Capsule, Capsule - Oral, Solution - Oral, Solution
Mood Disorders
, 25.0 mg, 100.0 mg, 200.0 mg, 50.0 mg, 150.0 mg, 15.0 mg, 23.0 mg, 46.0 mg, 69.0 mg, 92.0 mg, 25.0 meq, 25.0 mg/mL
, Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, extended release, Capsule, extended release - Oral, Capsule, coated pellets, Capsule, coated pellets - Oral, Capsule, Capsule - Oral, Solution - Oral, Solution
Chronic Weight Management therapy
, 25.0 mg, 100.0 mg, 200.0 mg, 50.0 mg, 150.0 mg, 15.0 mg, 23.0 mg, 46.0 mg, 69.0 mg, 92.0 mg, 25.0 meq, 25.0 mg/mL
, Oral, Tablet, Tablet - Oral, Tablet, film coated, Tablet, film coated - Oral, Tablet, coated, Tablet, coated - Oral, Capsule, extended release, Capsule, extended release - Oral, Capsule, coated pellets, Capsule, coated pellets - Oral, Capsule, Capsule - Oral, Solution - Oral, Solution

Warnings

Qudexy Xr Contraindications
Condition
Risk Level
Notes
Acidosis
Do Not Combine
There are 20 known major drug interactions with Qudexy Xr.
Common Qudexy Xr Drug Interactions
Drug Name
Risk Level
Description
Abemaciclib
Major
The metabolism of Abemaciclib can be increased when combined with Topiramate.
Acalabrutinib
Major
The metabolism of Acalabrutinib can be increased when combined with Topiramate.
Acenocoumarol
Major
The metabolism of Acenocoumarol can be increased when combined with Topiramate.
Alectinib
Major
The metabolism of Alectinib can be increased when combined with Topiramate.
Alpelisib
Major
The metabolism of Alpelisib can be increased when combined with Topiramate.
Qudexy Xr Toxicity & Overdose RiskThe toxic dose of topiramate in rats is above 1500 mg/kg. People who overdose on topiramate may experience symptoms such as low blood pressure, extreme acidity in the body, coma, stomach pain, vision problems, seizures, drowsiness, trouble speaking, confusion, dizziness, agitation, and depression. If the overdose is recent, doctors may suggest vomiting or pumping the stomach, as well as providing supportive care with activated charcoal and hemodialysis.

Qudexy Xr Novel Uses: Which Conditions Have a Clinical Trial Featuring Qudexy Xr?

313 active clinical trials are currently being conducted to assess the potential of Qudexy Xr to ameliorate Type 2 Diabetes, Migraine and Exercise-related issues.
Condition
Clinical Trials
Trial Phases
Exercise
59 Actively Recruiting
Not Applicable, Phase 2, Phase 3, Phase 1
Weight Loss
0 Actively Recruiting
Mood Disorders
0 Actively Recruiting
Migraine
52 Actively Recruiting
Phase 4, Not Applicable, Phase 2, Phase 1, Phase 3, Early Phase 1
Obesity
0 Actively Recruiting
Chronic Weight Management therapy
0 Actively Recruiting
Migraine Disorders
1 Actively Recruiting
Phase 3
Hypertensive disease
23 Actively Recruiting
Not Applicable, Phase 1, Phase 2, Phase 3
Seizures
4 Actively Recruiting
Phase 3, Phase 2
High cholesterol
0 Actively Recruiting
Obesity
0 Actively Recruiting
at least one weight-related comorbid condition
0 Actively Recruiting
Lennox Gastaut Syndrome
3 Actively Recruiting
Phase 2, Phase 1, Phase 4
Obesity
0 Actively Recruiting
Caloric Restriction
0 Actively Recruiting
Epilepsy
0 Actively Recruiting
Alcoholism
6 Actively Recruiting
Not Applicable, Phase 2, Phase 3
Type 2 Diabetes
174 Actively Recruiting
Not Applicable, Phase 1, Phase 2, Phase 3, Phase 4, Early Phase 1
increase in physical activity
0 Actively Recruiting

Qudexy Xr Reviews: What are patients saying about Qudexy Xr?

5Patient Review
9/11/2017
Qudexy Xr for Migraine Prevention
I use this because I have basilar migraines and i was on 100 mg of topomax xr but it stopped working for me so my neurologist bumped me up to 150mg to quedexy and it works great for me i have had no probelms! when i was taking the topomax I had tingling in my fingers and toes and knees and I also had nightmares for a month everytime I closed my eyes, but with quedexy I have never felt better!
2.7Patient Review
10/17/2016
Qudexy Xr for Migraine Prevention
I was previously taking topamax 100mg, but my doctor switched me to Qudexy at my annual visit. I found that I wasn't in a fog anymore, which was great! However, I experienced terrible stomach issues and bad tingling in my arms and legs. I tried staying with the medication for 3 weeks, but the stomach problems were too much to handle. I'm currently trying Trokendi to see if it will be more effective.
2Patient Review
1/14/2021
Qudexy Xr for Migraine Prevention
Although this medication did help to lessen my migraines by half, the hair loss after just three months was not worth it. Additionally, I frequently felt tingling in my fingers and toes while taking this drug.
1.7Patient Review
7/15/2016
Qudexy Xr for Migraine Prevention
I experienced a lot of negative side effects, like nausea and suicidal thoughts. This medication was ineffective for me, so I do not recommend it to others who are looking for relief from migraines.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about qudexy xr

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are the side effects of Qudexy XR?

"The following effects may occur: fatigue, drowsiness, dizziness, loss of coordination, tingling in the extremities, loss of appetite, changes in food taste, diarrhea, and weight loss."

Answered by AI

What is Qudexy XR used for?

"Qudexy XR is a prescription medicine that can be used to prevent migraine headaches in adults and adolescents 12 years and older, and to treat certain types of seizures (partial-onset seizures and primary generalized tonic-clonic seizures) in adults and children 2 years and older."

Answered by AI

Is Qudexy the same as topiramate?

"The active ingredient in both Topiramate Extended-Release Capsules and Qudexy® XR is topiramate. Topiramate Extended-Release Capsules are manufactured by Upsher-Smith, while Qudexy® XR is manufactured by UCB, Inc."

Answered by AI

Is Qudexy XR used for weight loss?

"No, you should not use Qudexy XR for weight loss. Although weight loss is a potential side effect of the medication, the main purpose of Qudexy XR is to help people with epilepsy or those who suffer from migraines."

Answered by AI

Clinical Trials for Qudexy Xr

Have you considered Qudexy Xr clinical trials? We made a collection of clinical trials featuring Qudexy Xr, we think they might fit your search criteria.
Have you considered Qudexy Xr clinical trials? We made a collection of clinical trials featuring Qudexy Xr, we think they might fit your search criteria.
Have you considered Qudexy Xr clinical trials? We made a collection of clinical trials featuring Qudexy Xr, we think they might fit your search criteria.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top